Symbiotec Pharmalab submits SEBI fair disclosure code to exchanges
- Symbiotec Pharmalab Limited submitted its fair disclosure code to BSE and NSE
- The filing complies with Regulation 8(2) of SEBI PIT Regulations, 2015
- Salil Jain, Company Secretary, signed the intimation on September 1, 2026
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information to the Bombay Stock Exchange and National Stock Exchange on September 1, 2026.
The filing was made pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company stated that the code is framed under Regulation 8(1) of the same regulations.
Salil Jain, Company Secretary and Compliance Officer, signed the intimation letter addressed to the Listing Departments of both exchanges. The submission serves as an informational record for the exchanges.
The registered office of Symbiotec Pharmalab Limited is located in Indore, Madhya Pradesh.
Historical Stock Returns for Symbiotec Pharmalab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +11.10% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
How might the formalization of Symbiotec Pharmalab's fair disclosure code impact investor confidence and stock liquidity in the near term?
Are there any pending regulatory audits or compliance reviews by SEBI that could trigger additional disclosures from the company following this filing?
Could this compliance update signal upcoming strategic announcements, such as new drug approvals or partnership deals, that require strict information control?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
